KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to -$79.4 million.

  • Acadia Pharmaceuticals' Cash from Investing Activities rose 3.77% to -$79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.5 million, marking a year-over-year increase of 18.62%. This contributed to the annual value of -$30.5 million for FY2024, which is 195.44% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Cash from Investing Activities of -$79.4 million as of Q3 2025, which was down 83.29% from -$43.3 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $192.5 million during Q1 2023, with a 5-year trough of -$194.3 million in Q2 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$43.3 million (2025), whereas its average is -$22.3 million.
  • In the last 5 years, Acadia Pharmaceuticals' Cash from Investing Activities skyrocketed by 35,301.73% in 2024 and then tumbled by 783.60% in 2025.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Cash from Investing Activities stood at $71.5 million in 2021, then plummeted by 124.81% to -$17.7 million in 2022, then soared by 98.04% to -$347,000 in 2023, then soared by 35,301.73% to $122.2 million in 2024, then grew by 3.77% to -$79.4 million in 2025.
  • Its Cash from Investing Activities was -$79.4 million in Q3 2025, compared to -$43.3 million in Q2 2025 and -$124.0 million in Q1 2025.